Skip to main content
Premium Trial:

Request an Annual Quote

Optivia Biotechnology Allies with Hurel

NEW YORK (GenomeWeb) – Optivia Biotechnologies and cell-based assays firm Hurel today announced they have reached a technology and marketing alliance..

The partnership will give researchers an array of powerful tools for in vitro studies of hepatic clearance and drug-induced liver injury, the firms said in a statement.

Under the terms of the agreement, North Brunswick, NJ-based Hurel will offer its new Hurelflux primary hepatocyte-based biliary clearance assay as a service in conjunction with Menlo Park, Calif.-based Optivia's menu of single and multi-transporter assay services. Both firms will market the package of services to their existing customers though they will only perform the assays each originally developed. The assays will also remain available as standalone services.

"Customers will now have a clearer picture of the mechanism of hepatic clearance and associated drug-drug interactions and what impact they may have in the clinic," Optivia CEO Yong Huang said in a statement.

Financial terms of the agreement were not disclosed.